Skip to content

Xencor XNCR Free cash flow

Free cash flow at other companies

Amgen logo
AmgenAMGN
$1.48B+50.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$12.61M+27.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$37.35M-68.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.94M-142%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$89.03M-44.3%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's free cash flow?
Xencor (XNCR) reported free cash flow of -$68.24M in Q1 2026.
How has Xencor's free cash flow changed year-over-year?
Xencor's free cash flow decreased by 286.3% year-over-year, from -$17.66M to -$68.24M.
What is the long-term trend for Xencor's free cash flow?
Over 2 years (2022 to 2025), Xencor's free cash flow has grown at a 214.2% compound annual growth rate (CAGR), from -$14.01M to -$138.27M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.